ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Comprehensive Analysis Reveals a 4-Gene Signature in Predicting Response to Temozolomide in Low-Grade Glioma Patients

Wang, Qi; He, Zongze*; Chen, Yong*电子科技大学; 四川省医学科学院(四川省人民医院); y
Cancer Control2019-6-3DOI: 10.1177/1073274819855118
7阅读
引用收藏
分享

摘要

Low-grade gliomas (LGGs) are a highly heterogeneous group of slow-growing, lethal, diffusive brain tumors. Temozolomide (TMZ) is a frequently used primary chemotherapeutic agent for LGGs. Currently there is no consensus as to the optimal biomarkers to predict the efficacy of TMZ, which calls for decision-making for each patient while considering molecular profiles. Low-grade glioma data sets were retrieved from The Cancer Genome Atlas. Cox regression and survival analyses were applied to identify clinical features significantly associated with survival. Subsequently, Ordinal logistic regression, co-expression, and Cox regression analyses were applied to identify genes that correlate significantly with response rate, disease-free survival, and overall survival of patients receiving TMZ as primary therapy. Finally, gene expression and methylation analyses were exploited to explain the mechanism between these gene expression and TMZ efficacy in LGG patients. Overall survival was significantly correlated with age, Karnofsky Performance Status score, and histological grade, but not with IDH1 mutation status. Using 3 distinct efficacy end points, regression and co-expression analyses further identified a novel 4-gene signature of ASPM, CCNB1, EXO1, and KIF23 which negatively correlated with response to TMZ therapy. In addition, expression of the 4-gene signature was associated with those of genes involved in homologous recombination. Finally, expression and methylation profiling identified a largely unknown olfactory receptor OR51F2 as potential mediator of the roles of the 4-gene signature in reducing TMZ efficacy. Taken together, these findings propose the 4-gene signature as a novel panel of efficacy predictors of TMZ therapy, as well as potential downstream mechanisms, including homologous recombination, OR51F2, and DNA methylation independent of MGMT.

学科与关键词

关键词
brain tumorlow-grade gliomatemozolomideEXO1CCNB1ASPMKIF23homologous recombination
相关
加载中…
  • A novel chemokine-based signature for prediction of prognosis and therapeutic response in glioma
    Fan, Wenhua; Wang, Di; Li, Guanzhang; Xu, Jianbao; Ren, Changyuan; Sun, Zhiyan; Wang, Zhiliang; Ma, Wenping; Zhao, Zheng; Bao, Zhaoshi; Jiang, Tao*; Zhang, Ying*CNS Neuroscience & Therapeutics, 2022, 28(12): 2090-2103.
  • A Qualitative Signature to Identify TERT Promoter Mutant High-Risk Tumors in Low-Grade Gliomas
    Zheng, Weicheng; Zhang, Ruolan; Huang, Ziru; Li, Jianpeng; Wu, Haonan; Zhou, Yuwei; Zhu, Jinwei; Wang, Xianlong*Frontiers in Molecular Biosciences, 2022, 9: 806727.被引 1
  • Identification of an IFN-β-associated gene signature for the prediction of overall survival among glioblastoma patients
    Cheng, Lijing; Yuan, Meiling; Li, Shu; Lian, Zhiying; Chen, Junjing; Lin, Weibiao; Zhang, Jianbo*; Zhong, Shupeng*Annals of Translational Medicine, 2021, 9(11): 925.被引 6
查看全部 →

发表信息

论文状态
公开发表
期刊
Cancer Control
发表日期
2019-06-03
卷期
第 26 卷, 第 1 期
页码
1073274819855118
DOI
10.1177/1073274819855118
语言
ENGLISH
成果收录
SCIE
资助标注
Health and Family Planning Commission of Sichuan Province, China [18PJ426]; Department of Science and Technology of Sichuan Province, China [2017SZ0203]

作者

  • W

    Wang, Qi (第一作者)

    sichuan prov peoples hosp · sichuan acad med sci

  • H

    He, Zongze (通讯)

    sichuan prov peoples hosp · sichuan acad med sci

查看全部 3 位作者收起作者
  • C

    Chen, Yong (通讯)

    sichuan prov peoples hosp · sichuan acad med sci

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417